Abstract 34P
Background
Social support is an important determinant of optimal care and maybe extended by community partners including non-governmental organizations to enhance the well-being of individuals living with cancer. We determined whether social support mediated the association between unmet needs and happiness in women with early breast cancer in a multiethnic Asian setting.
Methods
The study employed a hospital-based cross-sectional design that recruited 400 multiethnic patients newly diagnosed with early breast cancer in seven tertiary Malaysian hospitals. Study tools included Multi-dimensional Scale of Perceived Social Support, Needs Assessment Tool for Breast Cancer and Oxford, Happiness Questionnaire. Partial least square structural equation modelling was used to determine the mediating role of social support in the association between unmet needs and happiness.
Results
Participants comprised Malays (58.3%), followed by Chinese (26.8%), and Indians (12.3%). Two-thirds were recruited from Ministry of Health-owned hospitals, 20.5% from academic and 14.8% from private hospitals. A majority were diagnosed with stage II (32.3%) or stage III (30.0%) breast cancer at initial diagnosis. About 5.3% of participants reported to be unhappy, 5.8% somewhat unhappy, 8.3% rather unhappy, 30.3% somewhat happy, 28.7% rather happy, and 21.8% happy. A majority had moderate-level unmet supportive care needs (74%), with the highest level of unmet needs in the domains of information services (31.3%) and hospital appointments (30.3%). Sixty per cent reported a high level of social support. Unmet needs were found to have a negative and significant effect on happiness (f 2 =8.0%, β = −0.259, p < 0.001). Social support significantly, positively, and partially mediated the association between unmet needs and, with the p-values significant for both direct (p < 0.001) and indirect (p = 0.024) effects.
Conclusions
Social support plays an important role in bridging unmet needs and improving well-being of women with breast cancer. Study findings are expected to foster greater public-private partnerships in engaging communities to actively play a role in improving life after (breast) cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Ministry of Higher Education, Malaysia.
Disclosure
R. Kaur: Financial Interests, Personal, Speaker, Consultant, Advisor: Novartis, AstraZeneca, Pfizer, Roche,. M. Thiagarajan: Non-Financial Interests, Institutional, Leadership Role: Malaysian Oncological Society, President. N.F. Bt Abdul Satar: Financial Interests, Personal, Advisory Board: Novartis, Zuellig Pharma,Ipsen Pharma, Eisai, MSD Malaysia,Pfizer, Roche,; Financial Interests, Personal, Funding: KURA Oncology, Viracta Therapeutics, MSD Malaysia, Naluri Sdn Bhd; Financial Interests, Institutional, Principal Investigator: KURA Oncology, Viracta Therapeutics, MSD Malaysia, Naluri Sdn Bhd; Non-Financial Interests, Personal, Leadership Role: Project Lead for Cancer ECHO UM. A. Ali: Financial Interests, Personal, Invited Speaker: Roche, AstraZeneca. F.L.T. Chong: Financial Interests, Personal, Invited Speaker: Novartis, Roche,; Financial Interests, Personal and Institutional, Principal Investigator: Novartis, J&J. A.F. Abdul Aziz: Financial Interests, Personal, Invited Speaker: Roche; Non-Financial Interests, Institutional, Member of Board of Directors: National Cancer Society Malaysia; Non-Financial Interests, Institutional, Member: Fellow of College of Surgeons, Academy of Medicine Malaysia Member of Malaysian Oncological Society. C.H. Yip: Financial Interests, Personal, Advisory Board: AstraZeneca. N. Bhoo-Pathy: Financial Interests, Personal, Funding: Partial funding from Ministry of Higher Education. All other authors have declared no conflicts of interest.
Resources from the same session
123P - Spatial molecular profiling identifies FGF20 upregulation on cancer-associated fibroblast and FGFR2-PI3K/Akt activation in tumor cells of sporadic early-onset colon cancer
Presenter: Dave Hoon
Session: Poster Display
Resources:
Abstract
124P - Characteristics, prognosis and therapeutic effects of non-V600 BRAF mutated colorectal cancer
Presenter: Lalida Arsa
Session: Poster Display
Resources:
Abstract
125P - Final results of APOLLON-11 and SOYUZ-APOLLON study: Multicentre prospective observational post-authorization study of bevacizumab biosimilar in patients with metastatic colorectal cancer in real-world practice
Presenter: Alexey Tryakin
Session: Poster Display
Resources:
Abstract
126P - From tumor height (TH) to tumor regression grade (TRG) in locally advanced rectal cancers (LARC) during total neadjuvant therapy (TNT): A retrospective analysis
Presenter: Valeria Pusceddu
Session: Poster Display
Resources:
Abstract
127P - A meta-analysis of efficacy and safety from head-to-head first-line (1L) trials of epidermal growth factor receptor inhibitors (EGFRIs) versus bevacizumab in combination with chemotherapy (CT) doublets in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) by sidedness
Presenter: Takayuki Yoshino
Session: Poster Display
Resources:
Abstract
128TiP - A phase II study of cadonilimab + FOLFOXIRI and bevacizumab as initial therapy for unresectable proficient mismatch repair/microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC)
Presenter: Rongbo Lin
Session: Poster Display
Resources:
Abstract
140P - Prevalence of claudin-18 isoform 2 (CLDN18.2) positivity in locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mg/GEJ) adenocarcinoma in patients (pts) in the Asia region: Phase III SPOTLIGHT and GLOW studies
Presenter: Hoo Hwoei Fen Soo
Session: Poster Display
Resources:
Abstract
141P - Early phase trials outcomes in refractory upper GI cancers: A 10-year analysis from the SCRI UK phase I unit
Presenter: Antonella Cammarota
Session: Poster Display
Resources:
Abstract
142P - The survival impact of the addition of durvalumab to cisplatin/gemcitabine in advanced biliary tract cancer: A real-world, retrospective, multicentric study
Presenter: Silvia Foti
Session: Poster Display
Resources:
Abstract
143P - Ablation combined with tislelizumab in treating hepatocellular carcinoma: A phase II trial
Presenter: Yangxun Pan
Session: Poster Display
Resources:
Abstract